Last checked at 
(Alliance News) - Indivior PLC said on Thursday its strong start to 2022 had put it on track to meet its annual guidance as the company also announced a new USD100 million buyback.
The Virginia, US-base pharmaceutical company reported net income fell 49% in the first quarter against the previous year to USD41 million from USD80 million. Per share, earnings dropped 45% to USD0.06 from USD0.11.
Revenue rose 15% to USD207 million from USD180 million. The key growth driver was its Sublocade injection, which the company said is continuing to make good progress following the growth investments made in the second half of 2021.
Sublocade, a buprenorphine extended-release injection, is used in the treatment of opioid addiction. Total Sublocade patients were up 16% in the quarter to 57,000 from 49,000 the previous year.
Indivior said its guidance for 2022 remains unchanged. Previously, the company said expects its 2022 revenue to be between USD840 million to USD900 million. In 2021, revenue totalled USD791 million.
The company also announced a new share buyback programme of up to USD100 million as well as stating its intention for a possible listing of Indivior shares in the US.
Chief Executive Mark Crossley said: "We continue to consult widely with our shareholders on an additional US listing for Indivior shares and, if supported, we expect to seek formal shareholder approval in September of this year that would facilitate an additional listing in the US."
Shares in Indivior were up 3.3% at 333.80 pence on Thursday in London.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
